Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

871
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
871
Cancer Prevention02:59

Cancer Prevention

7.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Endometrial Stromal Sarcoma With Tumor Thrombus: A Rare Manifestation.

The journal of obstetrics and gynaecology research·2026
Same author

Authors' Response.

The Indian journal of medical research·2026
Same author

Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.

International journal of cancer·2026
Same author

Live surgical workshops: Balancing patient care and professional development.

The National medical journal of India·2026
Same author

A prospective cohort study comparing IADPSG and DIPSI criteria for diagnosing gestational diabetes and evaluating impact on maternal and neonatal health outcomes (DECIDE study protocol).

BMC pregnancy and childbirth·2026

Related Experiment Video

Updated: Dec 24, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.0K

Primary HPV screening for cervical cancer.

Neerja Bhatla1, Seema Singhal1

  • 1Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.

Best Practice & Research. Clinical Obstetrics & Gynaecology
|April 16, 2020
PubMed
Summary

Primary human papillomavirus (HPV) screening offers higher sensitivity for detecting cervical pre-cancer than cytology. Ensuring validated HPV tests and triage protocols is crucial for safe implementation and preventing over-treatment.

Keywords:
Cervical cancerEliminationHPV testScreeningTriage

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.0K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.8K

Related Experiment Videos

Last Updated: Dec 24, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.0K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.0K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.8K

Area of Science:

  • Oncology
  • Public Health
  • Molecular Diagnostics

Background:

  • Cytology-based cervical screening significantly reduced cervical cancer incidence and mortality.
  • Human papillomavirus (HPV) is recognized as the necessary cause of cervical cancer, driving the development of HPV testing.
  • Screening strategies have evolved from reflex HPV testing to co-testing and now primary HPV screening.

Purpose of the Study:

  • To review the evidence supporting the shift towards primary HPV screening for cervical cancer.
  • To highlight the advantages and challenges associated with implementing primary HPV screening.
  • To inform clinicians and policymakers on best practices for HPV-based cervical cancer screening.

Main Methods:

  • Review of evidence from large randomized controlled trials and meta-analyses.
  • Analysis of the evolution of cervical cancer screening methodologies.
  • Discussion of clinical validation requirements for HPV assays and triage protocols.

Main Results:

  • Primary HPV screening demonstrates higher sensitivity in detecting pre-neoplastic cervical lesions compared to cytology.
  • Negative primary HPV tests provide greater reassurance and allow for safe extension of screening intervals.
  • Successful implementation hinges on validated HPV testing and effective triage strategies for positive results.

Conclusions:

  • Primary HPV screening represents a more sensitive approach to cervical cancer detection.
  • Careful consideration of validated assays and triage protocols is essential to mitigate risks of over-treatment and healthcare burden.
  • The shift to primary HPV screening requires robust infrastructure and clinical guidelines for optimal patient outcomes.